Bank of Montreal Can Grows Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bank of Montreal Can increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 188,157 shares of the biopharmaceutical company’s stock after purchasing an additional 2,866 shares during the period. Bank of Montreal Can owned 0.17% of Regeneron Pharmaceuticals worth $196,189,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Rakuten Securities Inc. increased its stake in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $26,000. Sachetta LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. Finally, Family Firm Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.6 %

Shares of REGN stock opened at $749.51 on Tuesday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 12 month low of $735.95 and a 12 month high of $1,211.20. The stock has a market cap of $82.36 billion, a P/E ratio of 18.55, a P/E/G ratio of 2.84 and a beta of 0.15. The company has a 50 day simple moving average of $937.00 and a two-hundred day simple moving average of $1,025.99.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 7.48% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

REGN has been the subject of a number of recent research reports. BMO Capital Markets lowered their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. lowered their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Guggenheim increased their price objective on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. Finally, Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,099.55.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.